<DOC>
	<DOC>NCT02270983</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been present for a minimum of 3 months. This study includes up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients meeting the entry criteria will be randomized to 1 of 2 doses of linaclotide or placebo for 8 weeks. This 8-week study will assess the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of OIC.</brief_summary>
	<brief_title>Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<criteria>Patient has chronic noncancer pain that has been present for a minimum of 3 months Patient has been receiving a stable dose of a fullopioid agonist for at least 4 days per week during the 8 consecutive weeks Patient meets protocol criteria for OpioidInduced Constipation (OIC): &lt; 3 spontaneous bowel movements (SBMs) per week and reports one of the following symptoms for at least 4 weeks: 1. Straining during &gt; 25% of BMs 2. Lumpy or hard stools during &gt; 25% of BMs 3. Sensation of incomplete evacuation during &gt; 25% of BMs Patient meets the colonoscopy requirements defined by the American Gastroenterological Association guidelines Patient has successfully completed protocol procedures (with no clinically significant findings) Patient is compliant with Interactive Voice Response System (IVRS) for daily diary reporting Patient has a total of &lt; 6 SBMs in IVRS during the 14 days before and up to the time of Randomization Patient has adequate relief and wellcontrolled pain with current dose of opioid Patient has been using opioids for abdominal pain Patient has symptoms of or been diagnosed with chronic constipation or chronic idiopathic constipation prior to initiation of opioid treatment Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS) prior to initiation of opioid treatment Patient has a history of loose or watery stools for &gt; 25% of BMs during the 3 months before the Screening in the absence of laxatives, suppositories, or enemas Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility Patient has any protocolexcluded or clinically significant medical or surgical history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Opioid-Induced Constipation</keyword>
	<keyword>Linaclotide</keyword>
	<keyword>Linzess</keyword>
</DOC>